SX-682 + Docetaxel
NCT07667400
National Cancer Institute · Phase 1/2 · Recruiting · Enrollment 120
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
SX-682 + Docetaxel
National Cancer Institute · Phase 1/2 · Recruiting · Enrollment 120
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|
No efficacy figure is in this file for this study.